Trial · NCT02720510
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
NCT02720510, Phase 2, Terminated, Novartis Pharmaceuticals; results first posted 2018-07-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM). Trials, record NCT02720510. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02720510
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
- NCT number
- NCT02720510
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Multiple Myeloma
- Interventions
- Revlimid, Velcade, dexamethasone, Farydak
- First posted
- 2016-03-28
- Last updated
- 2018-07-24
- Results first posted
- 2018-07-24
- Limitations and caveats
- This study was terminated prematurely. The reason for study termination was not related to challenges linked to efficacy or safety data but instead, had faced unanticipated challenges with enrollment.
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients | 84 days | |
| Secondary | Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing | Month 3 | MRD negativity by Clonal Sequencing (ClonoSEQTM) assay (Adaptive Biotechnologies) |
| Secondary | Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance | Month 3 up to end of study, approximately 3 years. | ORR (CR + PR) and MRD negativity after ASCT and maintenance |
| Secondary | Depth of Response by International Myeloma Working Group (IMWG) Criteria | Day 22 up to end of study, approximately 3 years | Rate of Very Good Partial Response (VGPR), Complete Response (CR) and Stringent Complete Response (sCR) |
| Secondary | Duration of Response | From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years. | |
| Secondary | Overall Survival | 3 years after the last patient is enrolled to the study | |
| Secondary | Progression Free Survival | 3 years after the last patient is enrolled to the study |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients | 84 days | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. | ||
| SECONDARY | Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing | Month 3 | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. | ||
| SECONDARY | Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance | Month 3 up to end of study, approximately 3 years. | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. | ||
| SECONDARY | Depth of Response by International Myeloma Working Group (IMWG) Criteria | Day 22 up to end of study, approximately 3 years | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. | ||
| SECONDARY | Duration of Response | From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years. | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. | ||
| SECONDARY | Overall Survival | 3 years after the last patient is enrolled to the study | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated.. | ||
| SECONDARY | Progression Free Survival | 3 years after the last patient is enrolled to the study | The study was terminated prematurely and because only 6 patients were enrolled, efficacy data were not evaluated. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 - RVD + Pan | 3 | |
| Overall Study | STARTED | Arm 2 - RVD | 3 | |
| Overall Study | COMPLETED | Arm 1 - RVD + Pan | 0 | |
| Overall Study | COMPLETED | Arm 2 - RVD | 0 | |
| Overall Study | NOT COMPLETED | Arm 1 - RVD + Pan | 3 | |
| Overall Study | NOT COMPLETED | Arm 2 - RVD | 3 |
Source ClinicalTrials.gov
Adverse events80
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm 1- RVD+PAN | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Arm 2 - RVD | 1 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm 1- RVD+PAN | 0 | 3 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm 2 - RVD | 1 | 3 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm 1- RVD+PAN | 1 | 3 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Arm 2 - RVD | 0 | 3 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 1- RVD+PAN | 1 | 3 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 2 - RVD | 0 | 3 | |
| other | Constipation | Gastrointestinal disorders | Arm 1- RVD+PAN | 1 | 3 | |
| other | Constipation | Gastrointestinal disorders | Arm 2 - RVD | 1 | 3 |
1 to 10 of 80Source ClinicalTrials.gov
See all 80 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1- RVD+PAN | 0 | 3 |
| Total, all-cause mortality | Arm 2 - RVD | 0 | 3 |
| Total, other adverse events | Arm 1- RVD+PAN | 3 | 3 |
| Total, other adverse events | Arm 2 - RVD | 2 | 3 |
| Total, serious adverse events | Arm 1- RVD+PAN | 2 | 3 |
| Total, serious adverse events | Arm 2 - RVD | 1 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm 1- RVD+PAN vs Arm 2 - RVD: deaths from any cause | Trial comparisons |
| Arm 1- RVD+PAN vs Arm 2 - RVD: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02720510
GET https://conductscience.org/api/trials/v1/NCT02720510/events?page=2